Summary
p21/WAF1 expression was studied in a series of 162 colorectal carcinoma patients and its relation to p53- and activator protein (AP)-2 expressions and to stage as well as survival was assessed. p21 expression was moderate or intense in 33% of the tumours, and 53% of the tumours had moderate or strong p53 staining intensity. Eighty-nine percent of the tumours showed a weak cytoplasmic AP-2 signal. As expected, p21 and p53 stainings were inversely related to each other (P < 0.001). There was a significant positive association between p21 and AP-2 expression levels (P = 0.01). p21 intensity and percentage were higher in Dukes’ A and B stages (P < 0.001). The cancer-related survival and recurrence-free survival (RFS) rates were significantly lower among patients with a low signal for p21 (P < 0.001) and low p21 percentage in tumour epithelium (P < 0.001). High p53 staining intensity in tumour epithelium predicted poor survival (P = 0.01) and RFS (P = 0.003). In the multivariate analysis, p21 percentage distribution independently predicted cancer-related survival in all cases, and p21 expression intensity in T1–4/N0–3/M0 and T1–3/N0/M0 cases. p21 percentage distribution was an independent predictor of RFS in all and T1–3/ N0/M0 cases. AP-2 staining did not reach any prognostic significance. These results suggest that the immunohistochemical detection of cyclin-dependent kinase inhibitor p21 could be used to predict more precisely the outcome of colorectal cancer patients.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anttila, MA, Kosma, V-M, Hongxiu, J, Puolakka, J, Juhola, M, Saarikoski, S & Syrjänen, K (1999). p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79: 1870–1878.
Backe, J, Gassel, AM, Hauber, K, Krebs, S, Bartek, J, Caffier, H, Kreipe, HH, Muller-Hermelink, HK & Dietl, J (1997). p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 16: 361–368.
Bae, I, Fan, S, Bhatia, K, Kohn, KW, Fornace, AJ Jr & O’Connor, PM (1995). Relationships between G1 arrest and stability of the p53 and p21cip 1/waf1 proteins following gamma-irradiation of human lymphoma cells. Cancer Res 55: 2387–2393.
Bar-Eli, M (1997). Molecular mechanisms of melanoma metastasis. J Cell Physiol 173: 275–278.
Bennett, WP, El-Deiry, WS, Rush, WL, Guinee, DG, Freedman, AN, Caporaso, NE, Welsh, JA, Jones, RT, Borkowski, A, Travis, WD, Fleming, MV, Trastek, V, Pairolero, PC, Tazelaar, HD, Midthun, D, Jett, JR, Liotta, LA & Harris, CC (1998). p21 WAF/CIP1 and transforming growth factor β1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 4: 1499–1506.
Bosher, JM, Williams, T & Hurst, H (1995). The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92: 744–747.
Bukholm, IK, Nesland, JM, Kåresen, R, Jacobsen, U & Borresen, AL (1997). Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181: 140–145.
Byrne, RL, Horne, CHW, Robinson, MC, Autzen, P, Apakama, I, Bishop, RI, Neal, DE & Hamdy, FC (1997). The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 79: 190–195.
Caffo, O, Doglioni, C, Veronese, S, Bonzanini, M, Marchetti, A, Buttita, F, Fina, P, Leek, R, Morelli, L, Palma, PD, Harris, AL & Barbareschi, M (1996). Prognostic value of p21/WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 2: 1591–1599.
Chen, YQ, Cipriano, SC, Arenkiel, JM & Miller, FR (1995). Tumor suppression by p21/WAF1. Cancer Res 55: 4536–4539.
Clasen, S, Schulz, WA, Gerharz, C-D, Grimm, M-O, Cristoph, F & Schmitz-Dräger, BJ (1998). Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 77: 515–521.
Cox, DR (1972). Regression models and life tables with discussion. J Roy Stat Soc B 34: 187–192.
Diab, SG, Yu, YY, Hilsenbeck, SG, Allred, DC & Elledge, RM (1997). WAF1/CIP1 protein expression in human breast tumours. Breast Cancer Res Treat 43: 99–103.
Doglioni, C, Pelosio, P, Laurino, L, Macri, E, Meggiolaro, E, Favretti, F & Barbareschi, M (1996). p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 179: 248–253.
Elbendary, AA, Cirisano, FD, Evans, AC Jr, Davis, PL, Iglehart, JD, Marks, JR & Berchuck, A (1996). Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 2: 1571–1575.
Ellis, PA, Lonning, PE, Borresen-Dale, A, Aas, T, Geisler, S, Akslen, LA, Salter, I, Smith, IE & Dowsett, M (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer 76: 480–485.
Gee, MS, Sarkisian, CJ & El-Deiry, WS (1998). Identification of a novel AP-2 consensus DNA binding site. Biochem Biophys Res Commun 243: 307–316.
Haapasalo, H, Collan, Y, Atkin, NB, Pesonen, E & Seppä, A (1989). Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology 15: 167–178.
Hermanek, P & Sobin, LH (eds) (1987). TNM Classification of Malignant Tumours, 4th edn. Springer: Berlin
Hietala, KA, Kosma, V-M, Syrjänen, KJ, Syrjänen, SM & Kellokoski, JK (1997). Correlation of MIB-1 antigen expression with transcription factors Skn-1, Oct-1, AP-2, and HPV type in cervical intraepithelial neoplasia. J Pathol 183: 305–310.
Hirvikoski, P, Kumpulainen, E, Virtaniemi, J, Johansson, R, Haapasalo, H, Marin, S, Halonen, P, Helin, H, Raitiola, H, Pukander, J, Kellokumpu-Lehtinen, P & Kosma, VM (1997). p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol 15: 311–3120.
Ito, K, Sasano, H, Matsunaga, G, Sato, S, Yajima, A, Nasim, S & Garret, C (1997). Correlations between p21 expression and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183: 318–324.
Karjalainen, J, Kellokoski, J, Eskelinen, M, Alhava, E & Kosma, V-M (1998). Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 16: 3584–3591.
Karjalainen, JM, Eskelinen, MJ, Kellokoski, JK, Reinikainen, M, Alhava, EM & Kosma, V-M (1999). p21WAF1/CIP1 expression in stage I cutaneous malignant melanoma its relationship with p53, cell proliferation and survival. Br J Cancer 79: 895–902.
Li, YJ, Laurent-Puig, P, Salmon, RJ, Thomas, G & Hamelin, R (1995). Polymorphisms and probable lack of mutation in the waf-cip 1 gene in colorectal cancer. Oncogene 10: 599–601.
Macleod, KF, Sherry, N, Hannon, G, Beach, D, Tokino, T, Kinzler, K, Vogelstein, B & Jacks, T (1995). p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935–944.
Mantel, N & Haenszel, W (1992). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 51: 556–561.
Matsushita, K, Kobayashi, S, Kato, M, Itoh, Y, Okuyama, K, Sakiyama, S & Isono, K (1996). Reduced messenger RNA expression level of p21CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. Int J Cancer (Pred Oncol) 69: 259–264.
Ogawa, M, Maeda, K, Onoda, N, Chung, Y-S & Sowa, M (1997). Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 75: 1617–1620.
Ohue, M, Tomita, N, Monden, T, Fujita, M, Fukunaga, M, Takami, K, Yana, I, Ohnishi, T, Enomoto, T, Inoue, M, Shimano, T & Mori, T (1994). A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 54: 4798–4804.
Palazzo, JP, Mercer, WE, Kovatich, AJ & McHugh, M (1997). Immunohistochemical localization of p21 (WAF/CIP1) in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 28: 60–66.
Parker, SB, Eichele, G, Zhang, P, Rawls, A, Sands, AT, Bradley, A, Olson, EN, Harper, JW & Elledge, SJ (1995). p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267: 1024–1027.
Polyak, K, Waldman, T, He, TC, Kinzler, KW & Vogelstein, B (1996). Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945–1952.
Rey, MJ, Fernandez, PL, Jares, P, Munoz, M, Nadal, A, Peiro, N, Nayach, I, Mallofre, C, Muntane, J, Campo, E, Estape, J & Cardesa, A (1998). p21 WAF/Cip 1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol 184: 265–271.
Ropponen, KM, Eskelinen, MJ, Lipponen, PK, Alhava, E & Kosma, V-M (1997). Prognostic value of tumour infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318–324.
Sasaki, K, Sato, K, Kurose, A & Ikeda, E (1996). Immunohistochemical detection of p21WAF1/CIP1/SDI1 and p53 proteins in formalin-fixed, paraffin-embedded tissue sections of colorectal carcinoma. Hum Pathol 27: 912–916.
Slebos, RJC, Baas, IO, Clement, M, Polak, M, Mulder, J-W, van den Berg, FM, Hamilton, SR & Offerhaus, GJA (1996). Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 74: 165–171.
Tenan, M, Carrara, F, Di Donato, S & Finocchiaro, G (1995). Absence of mutations and identification of two polymorphism in the SSCP and sequence analysis of p21CKI gene in malignant gliomas. Int J Cancer 62: 115–117.
Turnbull, RB, Kyle, K, Watson, FB & Spratt, J (1967). Cancer of the colon: the influence of the no-touch isolation technique on survival rates. Ann Surg 166: 400–427.
Wang, A, Yoshimi, N, Ino, N, Tanaka, T & Mori, H (1997). WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 123: 118–123.
Werness, BA, Jobe, JS, DiCioccio, A & Piver, MS (1997). Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol 16: 149–155.
Yasui, W, Akama, Y, Yokozaki, H, Semba, S, Kudo, Y, Shimamoto, F & Tahara, E (1997). Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. Pathol Int 47: 470–477.
Zhang, W, Grasso, L, McClain, CD, Gambel, AM, Cha, Y, Salvatore, T, Deisseroth, AB & Mercer, WE (1995). p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668–674.
Zeng, Y-X, Somasundaram, K & El-Deiry, WS (1997). AP2 inhibits cancer cells growth and activates p21WAF1/CIP1 expression. Nat Genet 15: 78–82.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ropponen, K., Kellokoski, J., Lipponen, P. et al. p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br J Cancer 81, 133–140 (1999). https://doi.org/10.1038/sj.bjc.6690662
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690662
Keywords
This article is cited by
-
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer
Modern Pathology (2020)
-
Thymidylate synthase expression and p21WAF1/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy
Cellular Oncology (2014)
-
AP-2α expression and cell apoptosis of the lung tissue of rats with COPD and ECV304 cells stimulated by cigarette smoke extract
Chinese Science Bulletin (2011)
-
Expression of p21WAF1 in Astler–Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy
Virchows Archiv (2011)
-
Decreased p21 Expression in HPV-18 Positive Cervical Carcinomas
Pathology & Oncology Research (2010)